Antineoplastics
1
Reactions 1332 - 18 Dec 2010 S Antineoplastics Various toxicities: case report A 33-year-old man, who was HIV positive, started receiving cyclophosphamide, vincristine, doxorubicin, prednisone (CHOP) combined with rituximab [routes and dosages not stated] for the treatment of diffuse large B-cell lymphoma. During therapy, he developed skin ulcerations, diarrhoea, stomatitis and myelosuppression [time to reaction onsets not stated]. He was given filgrastim for leucopenia, as well as ceftriaxone and fluconazole. His platelet and erythrocyte counts spontaneously improved. Additionally, he was given chlorhexidine to treat stomatitis. However, his reactions became worse during each subsequent chemotherapy cycle. Additionally, he developed asthenia and cachexia [time to reaction onsets not stated]. He died following his fifth chemotherapy cycle. Author comment: "[T]he risk of increased toxicities in patients treated for lymphomas and who are receiving HAART is slightly higher than in HIV-negative patients." Czepiel J, et al. The case of a diffuse large B-cell lymphoma (DLBCL) in a course of HIV. HIV and AIDS Review 9: 22-25, No. 1, 2010 - Poland 803046200 1 Reactions 18 Dec 2010 No. 1332 0114-9954/10/1332-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
-
Upload
truongthien -
Category
Documents
-
view
212 -
download
0
Transcript of Antineoplastics
Reactions 1332 - 18 Dec 2010
SAntineoplastics
Various toxicities: case reportA 33-year-old man, who was HIV positive, started
receiving cyclophosphamide, vincristine, doxorubicin,prednisone (CHOP) combined with rituximab [routes anddosages not stated] for the treatment of diffuse large B-celllymphoma. During therapy, he developed skin ulcerations,diarrhoea, stomatitis and myelosuppression [time toreaction onsets not stated]. He was given filgrastim forleucopenia, as well as ceftriaxone and fluconazole. Hisplatelet and erythrocyte counts spontaneously improved.Additionally, he was given chlorhexidine to treat stomatitis.However, his reactions became worse during eachsubsequent chemotherapy cycle. Additionally, hedeveloped asthenia and cachexia [time to reaction onsetsnot stated]. He died following his fifth chemotherapy cycle.
Author comment: "[T]he risk of increased toxicities inpatients treated for lymphomas and who are receiving HAARTis slightly higher than in HIV-negative patients."Czepiel J, et al. The case of a diffuse large B-cell lymphoma (DLBCL) in a courseof HIV. HIV and AIDS Review 9: 22-25, No. 1, 2010 - Poland 803046200
1
Reactions 18 Dec 2010 No. 13320114-9954/10/1332-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
